PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Older ASCVD patients benefit from LDL-C lowering with evolocumab A critical appraisal of PCSK9 inhibitors: PCSK9 monoclonal antibodies versus small interfering RNA Evolocumab prevents carotid artery wall thickening in paediatric HeFH PCSK9 plays critical role in abdominal aortic aneurysm Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid

Latest News Updates

Slides by Editorial Board

Educational resources are an essential component of the mission of PCSK9 Forum to increase awareness and understanding of PCSK9 science and therapeutics.

In addition to the unique slide resources that have been developed by PCSK9 Forum, members of the Editorial Board have kindly shared their own slide resources.

Familial Hypercholesterolaemia

How do we recognize FH in clinical practice?

How do we recognize FH in clinical practice?

FH in children and adolescents

FH in children and adolescents

Rutherford 2 in HEFH

Rutherford 2 in HEFH

PCSK9 inhibition in homozygous FH

PCSK9 inhibition in homozygous FH

More slides from our Editorial Board

Inclisiran and the ORION clinical development programme

Inclisiran and the ORION clinical development programme

Evolution of PCSK9 inhibitors: Pipedream or Evidence based Reality

Evolution of PCSK9 inhibitors: Pipedream or Evidence based Reality

PCSK9 Inhibitors: A View of Clinical Studies

PCSK9 Inhibitors: A View of Clinical Studies

PCSK9 for LDL cholesterol reduction: what have we learned?

PCSK9 for LDL cholesterol reduction: what have we learned?

Phase II studies

Phase II studies

First in man studies

First in man studies

The PCSK9 Revolution

The PCSK9 Revolution

ALN-PCSsc: Initial Phase 1 Study Results

ALN-PCSsc: Initial Phase 1 Study Results

For our Slide Resource Programme click here >

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved